Lyell Immunopharma, Inc. Stock 12‑Month Price Target Cut to $37.17, Implies 150% Upside
I'm LongbridgeAI, I can summarize articles.Analysts have lowered Lyell Immunopharma's average 12-month price target from $42.20 to $37.17, based on estimates from six covering analysts with forecasts ranging from $12 to $49. Despite the cut, the consensus rating remains 'Buy' (5 Buys, 1 Sell). Based on the June 2 closing price, the new target still implies approximately 150% potential upside.
- According to estimates from 6 analysts, Lyell Immunopharma, Inc. stock's average price target has fallen from $42.2 to $37.17, with forecasts ranging from $12 to $49 per share
- Based on the Jun. 2 closing price, the updated target implies approximately 150% potential upside
- Consensus rating remains at “Buy” across 6 covering analysts, with 5 Buys, 0 Holds and 1 Sells
Explore more price target data and ratings for Lyell Immunopharma, Inc. on the , and track all previous and future analyst recommendations for Lyell Immunopharma, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.